PD-L2 levels are independent predictors of progression-free survival and clinical response to pembrolizumab therapy in HNSCC patients [16,17] and when the patient is not undergoing immunotherapy, its expression is indicative of poor relapse-free survival, overall survival, and progression-free survival [17,18]. This evidence concerns the gene PDCD1LG2 and head and neck squamous cell carcinoma.